PURPOSE: Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. METHODS: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. RESULTS: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. CONCLUSION: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
PURPOSE:Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. METHODS: We retrospectively assessed data of 120 SCLCpatients who failed first-line treatment and received second-line treatment at three medical oncology centers. RESULTS: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. CONCLUSION:Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Authors: J von Pawel; J H Schiller; F A Shepherd; S Z Fields; J P Kleisbauer; N G Chrysson; D J Stewart; P I Clark; M C Palmer; A Depierre; J Carmichael; J B Krebs; G Ross; S R Lane; R Gralla Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: J Jassem; H Karnicka-Młodkowska; C van Pottelsberghe; M van Glabbeke; M A Noseda; A Ardizzoni; F Gozzelino; A Planting; N van Zandwijk Journal: Eur J Cancer Date: 1993 Impact factor: 9.162
Authors: N Masuda; M Fukuoka; Y Kusunoki; K Matsui; N Takifuji; S Kudoh; S Negoro; M Nishioka; K Nakagawa; M Takada Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: Primo N Lara; James Moon; Mary W Redman; Thomas J Semrad; Karen Kelly; Jeffrey W Allen; Barbara J Gitlitz; Philip C Mack; David R Gandara Journal: J Thorac Oncol Date: 2015-01 Impact factor: 15.609
Authors: Damian von Eiff; Farastuk Bozorgmehr; Inn Chung; Denise Bernhardt; Stefan Rieken; Stephan Liersch; Thomas Muley; Sonja Kobinger; Michael Thomas; Petros Christopoulos; Martin Steins Journal: J Thorac Dis Date: 2020-03 Impact factor: 2.895
Authors: Seo Ree Kim; Ji Hyung Hong; Soo-Yoon Sung; Yeo Hyung Kim; Sang Hoon Chun; Hyun Woo Lee; Jung Soo Lee; Yoon Ho Ko Journal: BMC Cancer Date: 2021-03-31 Impact factor: 4.430
Authors: Manjiao Ma; Mengzhao Wang; Yan Xu; Ke Hu; Huihui Liu; Longyun Li; Wei Zhong; Li Zhang; Jing Zhao; Huazhu Wang Journal: Zhongguo Fei Ai Za Zhi Date: 2013-11